Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies

  1. Ana Rita Pombo Antunes
  2. Isabelle Scheyltjens
  3. Johnny Duerinck
  4. Bart Neyns
  5. Kiavash Movahedi  Is a corresponding author
  6. Jo A Van Ginderachter  Is a corresponding author
  1. VIB Center for Inflammation Research, Belgium
  2. Vrije Universiteit Brussel, Belgium
  3. UZ Brussels, Belgium
1 figure

Figures

Heterogeneity of the glioblastoma immune microenvironment and potential therapeutic targets.

Within glioblastoma tumors reside ontogenically distinct, immunoregulatory macrophages (Sall1+ tumor microglia, Sall1- monocyte-derived macrophages), immunosuppressive Treg (eg CCR8+) and dysfunctional T-cell populations (CTLA-4/PD-1hi). Not much is known about intratumoral DC subsets, although distinct DC populations are found in other brain regions, such as the dura mater (Van Hove et al., 2019). Glioblastoma also affects the phenotype of classical monocytes (Cl. Monocyte) in the periphery, which acquire an immunosuppressive (MDSC-like?) phenotype. Notably, the genetic make-up of the cancer cells (blue rectangle) and potentially also of the glioblastoma stem cells, affect the immune composition of the tumor, with for example a higher presence of lymphocytes in TCGA-MES tumors. Several potential therapeutic targets (CSF1R, SIRPa, CCR8, PD-1, CTLA-4), either already tested in the clinic or promising for the future, are highlighted.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ana Rita Pombo Antunes
  2. Isabelle Scheyltjens
  3. Johnny Duerinck
  4. Bart Neyns
  5. Kiavash Movahedi
  6. Jo A Van Ginderachter
(2020)
Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
eLife 9:e52176.
https://doi.org/10.7554/eLife.52176